Questions Surrounding iPS Cells in Japan

Two years ago, the first clinical application study of iPS cells began with age-related macular degeneration. At first, six cases were scheduled. However, last year, for the second patient, the operation was stopped due to the genetic mutation of iPS cells from this patient. This genetic mutation was reported to be the absence of some genetic information. The risk of developing cancer also could not be excluded. The carcinogenicity of iPS cells, therefore, remains unresolved. It appears that from now, instead of using costly and time-consuming iPS cells from each patient, stocked iPS cells from healthy donors with homozygous HLA (human leukocyte antigen), for which the safety is checked beforehand, are going to be used. In regard to this, I have some misgivings. In the first place, the superiority of iPS cells over ES cells is that one can use the patient’s own cells (tissue), which does not carry the risk of the rejection and resolves ethical issues. As previously planned, I think the remaining five patients should be operated on using the patients’ own cells. The cost and time is not an issue only for these five patients. On obtaining successful results and experiences with these six patients, as the next step, stocked iPS cells should be applied carefully. The phrase "Make haste slowly" comes to my mind. Is this a groundless concern by a non-professional layperson?